A novel oriented antibody immobilization based voltammetric immunosensor for allergenic activity detection of lectin in kidney bean by using AuNPs-PEI-MWCNTs modified electrode

Publication date: 15 October 2019Source: Biosensors and Bioelectronics, Volume 143Author(s): Xianbao Sun, Yongkang Ye, Shudong He, Zeyu Wu, Junyang Yue, Hanju Sun, Xiaodong CaoAbstract:As a well-known allergenic indicator in kidney beans, lectins have always been the serious threats for human health. Herein, we introduced a new label-free voltammetric immunosensor for the direct determination of kidney bean lectin (KBL) with potential allergenic activity. Gold nanoparticles-polyethyleneimine-multiwalled carbon nanotubes nanocomposite was one-pot synthesized and modified onto the glass carbon electrode to enhance catalytic currents of oxygen reduction reaction. The KBL polyclonal antibody, acquired from rabbit immunization, was orientedly immobilized on the electrode modified with recombinant staphylococcal protein A via fragment crystallizable (Fc) region of antibody. Under the optimized condition, the immunosensor displayed a good linear response (R2 = 0.978) to KBL with a range from 0.05 to 100 μg/mL and a detection limit of 0.023 μg/mL. Simultaneously, the immunosensor exhibited well selectivity, interference-resistant ability, stability (4 °C) and reproducibility. Compared with the conventional enzyme-linked immunosorbent assay (ELISA) method, the immunosensor was successfully applied to quantify allergenic activity of lectin in raw and cooked (boiled for 30 min) kidney bean milk samples. This new approach provides new perspectives both for rapid qua...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research

Related Links:

Aimmune Therapeutics Inc.'s quest to sell the first biologic drug to treat peanut allergies won a regulatory advisory committee's blessing Friday, moving the company closer to Food and Drug Administration approval. The action by the nine-member panel doesn't guarantee that the FDA will approve the drug, which would be branded as Palforzia, from Brisbane-based Aimmune (NASDAQ: AIMT). Advisory committee recommendations, however, typically hold great sway with the regulator. Palforzia is groundbreaking,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Publication date: Available online 15 September 2019Source: The Lancet HIVAuthor(s): Joseph Kagaayi, Larry W Chang, Victor Ssempijja, M Kate Grabowski, Robert Ssekubugu, Gertrude Nakigozi, Godfrey Kigozi, David M Serwadda, Ronald H Gray, Fred Nalugoda, Nelson K Sew.ambo, Lisa Nelson, Lisa A Mills, Donna Kabatesi, Stella Alamo, Caitlin E Kennedy, Aaron A R Tobian, John S Santelli, Anna Mia Ekström, Helena NordenstedtSummaryBackgroundTargeting combination HIV interventions to locations and populations with high HIV burden is a global priority, but the impact of these strategies on HIV incidence is unclear. We assessed t...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research
An FDA advisory panel recommended peanut allergen powder (Palforzia, Aimmune Therapeutics) for children aged 4 years through 17 years who are allergic to peanuts.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Alison Morris is the Division Chief, Pulmonary, Allergy and Critical Care Medicine, at the University of Pittsburgh Department of Medicine.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Some allergy sufferers say they are "terrified" when dining out and have asked eateries to do more to make them safe.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
A London restaurant did not tell Owen Carey that his last meal was soaked in something that could kill him, a coroner concluded.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
This article summarizes the most important treatment modalities based on case reports and series, clinical studies, guidelines and expert recommendations. PMID: 31515578 [PubMed - as supplied by publisher]
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
Publication date: Available online 13 September 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Emmanuel Ledoult, Matthieu Groh, Jean-Emmanuel Kahn, Jacques Trauet, Jean-David Bouaziz, Aurélie Caristan, Vincent Cottin, Sylvain Dubucquoi, Nicolas Etienne, Cécile Golden, Perrine Guillaume-Jugnot, Éric Hachulla, David Launay, Irène Machelart, Adèle De Masson, Thomas Molinet, Chafika Morati-Hafsaoui, Marie Puget, Mathilde Roumier, Louis Terriou
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
U.S. health officials on Thursday cut the number of lung illnesses linked to e-cigarettes and vaping products under investigation to 380 as states began assessing patients based on a narrower case definition issued late last month by the Centers for Disease Control and Prevention (CDC).Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Public Health & Prevention News Source Type: news
The US Food and Drug Administration's Allergenic Products Advisory Committee on Friday voted in favor of approving a treatment for peanut allergies in children.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
More News: Allergy | Allergy & Immunology | Biotechnology | Milk | Nanotechnology | Urology & Nephrology